Results 121 to 130 of about 102,706 (265)

Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs. [PDF]

J Endocr Soc
Kamrul-Hasan ABM, Uday S, Nagendra L, Dutta D, Bhattacharya S, Pappachan JM, Ashraf AP.   +6 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Perspectives on C-Type Natriuretic Peptide in Cardiometabolic Disease. [PDF]

J Am Heart Assoc
Goetze JP, Yanagisawa H, Kinoshita H, Burnett J, Nyberg M, Nishikimi T.   +5 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Recombinant human brain natriuretic peptide for the recovery stage of septic shock: an interventional study protocol. [PDF]

BMJ Open
Luo JC, Mou T, Li M, Feng WT, Yue RM, Pan C, Huang XB, Kattan E, Zhang Y, Pan LA.   +9 more
europepmc   +1 more source

Impaired Atrial Natriuretic Peptide Secretion as a Marker of Advanced Atrial Fibrillation. [PDF]

Circ Rep
Oka S, Miyamoto K, Asahina C, Nakamura T, Wakamiya A, Ueda N, Nakajima K, Kamakura T, Wada M, Ishibashi K, Inoue Y, Aiba T, Kusano K.   +12 more
europepmc   +1 more source

Correction: Natriuretic peptide signaling as a therapeutic target in POTS: physiological opportunities and caveats. [PDF]

Clin Auton Res
Jordan J, Pesta D, Moro C.
europepmc   +1 more source

Flexible wearable electronics for cardiovascular monitoring from surface signals to deep physiological insights

FlexMat, EarlyView.
This review organizes flexible wearable electronics for cardiovascular monitoring into four interconnected information layers: surface electrophysiology, hemodynamic sensing, vascular imaging, and biofluid biomarker analysis. This framework clarifies how electrical rhythm, vascular loading, structural and flow‐related features, and biochemical states ...
Qiao Chen, Hongwen Chen, Yuanyuan Li, Pingan Yang, Rui Li, Zhihao Zhou   +5 more
wiley   +1 more source

Natriuretic peptide signaling as a therapeutic target in POTS: physiological opportunities and caveats. [PDF]

Clin Auton Res
Jordan J, Pesta D, Moro C.
europepmc   +1 more source

Asymptomatic Cardiotoxicity After High‐Dose Anthracycline Treatment in Sarcoma Patients Assessed by Biomarkers and Echocardiography

International Journal of Cancer, EarlyView.
ABSTRACT Treatment of sarcoma includes high‐dose anthracyclines, which can cause cardiotoxicity. This study assesses the correlation of cardiac biomarkers and echocardiographic parameters on asymptomatic cardiotoxicity in sarcoma patients treated with anthracyclines.
Elissa A. S. Polomski, Frank M. Speetjens, J. Wouter Jukema, Julius C. Heemelaar, Michiel A. J. van de Sande, Hans Gelderblom, M. Louisa Antoni   +6 more
wiley   +1 more source